Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.
AIM
Microarray studies identified a subgroup of molecular apocrine tumors (estrogen receptor [ER] negative/androgen receptor [AR] positive) that express luminal genes including FOXA1. FOXA1 may direct AR to sites normally occupied by ER in luminal tumors, inducing an estrogen-like gene program that stimulated proliferation.


MATERIALS & METHODS
Expression of AR and FOXA1 was evaluated by immunohistochemistry in 592 patients with nonmetastatic triple-negative breast cancer (TNBC).


RESULTS
Coexpression of AR and FOXA1 was found in 15.2% of patients. These tumors were more frequently lobular, found in older patients and exhibited a lower nuclear grade and a greater degree of node involvement. They less often exhibited lymphocytic infiltrate, pushing margins, syncytial architecture, central fibrosis or necrosis.


CONCLUSION
TNBC with coexpression of AR and FOXA1 seems to behave like luminal tumors with a morphological profile distinct from other TNBC. These biomarkers could be useful to identify a subgroup of TNBC and could have future therapeutic implications.
['Guiu|Séverine|S|', 'Charon-Barra|Céline|C|', 'Vernerey|Déwi|D|', 'Fumoleau|Pierre|P|', 'Campone|Mario|M|', 'Spielmann|Marc|M|', 'Roché|Henri|H|', 'Mesleard|Christel|C|', 'Arnould|Laurent|L|', 'Lemonnier|Jérôme|J|', 'Lacroix-Triki|Magali|M|']
D000328:Adult D000971:Antineoplastic Combined Chemotherapy Protocols D005260:Female D015870:Gene Expression D051541:Hepatocyte Nuclear Factor 3-alpha D006801:Humans D007150:Immunohistochemistry D008875:Middle Aged D060787:Neoplasm Grading D009367:Neoplasm Staging D016017:Odds Ratio D011944:Receptors, Androgen D064726:Triple Negative Breast Neoplasms D047368:Tumor Burden
androgen receptor FOXA1 triple-negative breast cancer molecular apocrine tumors